Royalty Pharma plc financial data

Symbol
RPRX on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 11 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 190% % -31%
Return On Equity 8% % -6.6%
Return On Assets 4.1% % -16%
Operating Margin 66% % 15%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $16,700,000,000 USD 27%
Weighted Average Number of Shares Outstanding, Basic 429,801,000 shares -4.1%
Weighted Average Number of Shares Outstanding, Diluted 564,455,000 shares -5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,378,193,000 USD 5.1%
Research and Development Expense $452,000,000 USD 22500%
General and Administrative Expense $573,481,000 USD 142%
Costs and Expenses $818,675,000 USD -16%
Operating Income (Loss) $1,559,518,000 USD 21%
Nonoperating Income (Expense) $235,326,000 USD -713%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,324,192,000 USD -0.5%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $770,947,000 USD -10%
Earnings Per Share, Basic 1.79 USD/shares -6.8%
Earnings Per Share, Diluted 1.78 USD/shares -6.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $618,696,000 USD -33%
Other Assets, Current $6,893,000 USD 65%
Assets, Current $1,528,091,000 USD -15%
Goodwill $924,634,000 USD
Other Assets, Noncurrent $79,293,000 USD 136%
Assets $19,620,780,000 USD 7.7%
Liabilities, Current $636,211,000 USD -49%
Other Liabilities, Noncurrent $120,843,000 USD 900%
Liabilities $9,905,841,000 USD 26%
Retained Earnings (Accumulated Deficit) $2,356,318,000 USD -17%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $9,714,939,000 USD -6.1%
Liabilities and Equity $19,620,780,000 USD 7.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $596,076,000 USD -10%
Net Cash Provided by (Used in) Financing Activities $941,299,000 USD -344%
Net Cash Provided by (Used in) Investing Activities $503,917,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $158,694,000 USD -57%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $618,696,000 USD -33%
Interest Paid, Excluding Capitalized Interest, Operating Activities $138,822,000 USD 76%
Operating Lease, Liability $19,257,000 USD
Lessee, Operating Lease, Liability, to be Paid $22,160,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,776,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $4,053,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,903,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,721,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,726,000 USD
Additional Paid in Capital $4,123,088,000 USD 0.48%
Share-based Payment Arrangement, Expense $73,353,000 USD 10188%
Interest Expense $184,469,000 USD -1.8%